HICKY Funding Boosts Central Sleep Apnea Device Development

HICKY, a Japanese medtech innovator, has secured crucial funding from the Tokyo Wellness Impact Fund and the Regional, People, and Future (CJS No. 2 Fund). This investment will accelerate the development of its novel stent-type neurostimulation device designed to treat central sleep apnea (CSA), a condition often linked to heart failure and significantly impacting patient quality of life.

The company's proprietary technology aims to restore natural breathing patterns by directly stimulating the phrenic nerve. Unlike existing treatments that often require external hardware and invasive procedures, HICKY's device is designed for intravascular placement. This innovative approach minimizes the need for subcutaneous generators and external leads, thereby reducing the risk of complications associated with such components and potentially shortening procedure times for patients.

Central sleep apnea affects a substantial portion of heart failure patients, estimated at around 40%, leading to diminished sleep quality, exacerbation of cardiac conditions, and increased hospital readmissions. The current therapeutic options for CSA are notably limited, leaving a significant unmet medical need. HICKY's technology offers a promising alternative by addressing the root cause of the condition through targeted nerve stimulation.

The newly acquired capital will be strategically deployed across several key areas. These include refining the device's miniaturization and overall design, advancing crucial preclinical and clinical trial stages, preparing for regulatory submissions such as Q-Sub and IDE applications, and building a robust global clinical collaboration network. This comprehensive approach underscores HICKY's commitment to bringing its innovative solution to market efficiently and effectively.

Further bolstering its development trajectory, HICKY also benefits from the support of the Japan Agency for Medical Research and Development (AMED). Having successfully passed its interim review, the company is assured of continued backing from AMED through fiscal year 2026, providing a stable foundation for its long-term research and development efforts. This dual support from private and public entities highlights the perceived potential of HICKY's therapeutic approach.

The market for sleep disorder treatments is substantial, with the global sleep apnea devices market projected to grow significantly in the coming years, driven by increasing awareness, rising prevalence of obesity and cardiovascular diseases, and technological advancements. HICKY's minimally invasive, leadless neurostimulation device is well-positioned to capture a share of this expanding market by offering a differentiated and potentially superior treatment option for CSA patients.